AU2013272330B2 - Selection and use of lactic acid bacteria preventing bone loss in mammals - Google Patents

Selection and use of lactic acid bacteria preventing bone loss in mammals Download PDF

Info

Publication number
AU2013272330B2
AU2013272330B2 AU2013272330A AU2013272330A AU2013272330B2 AU 2013272330 B2 AU2013272330 B2 AU 2013272330B2 AU 2013272330 A AU2013272330 A AU 2013272330A AU 2013272330 A AU2013272330 A AU 2013272330A AU 2013272330 B2 AU2013272330 B2 AU 2013272330B2
Authority
AU
Australia
Prior art keywords
bone loss
reuteri
base pair
bone
lactic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013272330A
Other languages
English (en)
Other versions
AU2013272330A1 (en
Inventor
Robert Allen Britton
Eamonn Connolly
Laura Rae MCCABE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogaia AB
Michigan State University
Original Assignee
Biogaia AB
Michigan State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia AB, Michigan State University filed Critical Biogaia AB
Publication of AU2013272330A1 publication Critical patent/AU2013272330A1/en
Application granted granted Critical
Publication of AU2013272330B2 publication Critical patent/AU2013272330B2/en
Priority to AU2018200524A priority Critical patent/AU2018200524B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2013272330A 2012-06-04 2013-06-04 Selection and use of lactic acid bacteria preventing bone loss in mammals Ceased AU2013272330B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018200524A AU2018200524B2 (en) 2012-06-04 2018-01-23 Selection and use of lactic acid bacteria preventing bone loss in mammals

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261689338P 2012-06-04 2012-06-04
US61/689,338 2012-06-04
PCT/SE2013/050646 WO2013184064A1 (en) 2012-06-04 2013-06-04 Selection and use of lactic acid bacteria preventing bone loss in mammals

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018200524A Division AU2018200524B2 (en) 2012-06-04 2018-01-23 Selection and use of lactic acid bacteria preventing bone loss in mammals

Publications (2)

Publication Number Publication Date
AU2013272330A1 AU2013272330A1 (en) 2015-01-15
AU2013272330B2 true AU2013272330B2 (en) 2017-11-02

Family

ID=49712339

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013272330A Ceased AU2013272330B2 (en) 2012-06-04 2013-06-04 Selection and use of lactic acid bacteria preventing bone loss in mammals
AU2018200524A Ceased AU2018200524B2 (en) 2012-06-04 2018-01-23 Selection and use of lactic acid bacteria preventing bone loss in mammals

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018200524A Ceased AU2018200524B2 (en) 2012-06-04 2018-01-23 Selection and use of lactic acid bacteria preventing bone loss in mammals

Country Status (16)

Country Link
US (4) US20150150917A1 (enExample)
EP (2) EP2854826B9 (enExample)
JP (1) JP6193981B2 (enExample)
KR (2) KR102191537B1 (enExample)
CN (1) CN104755091B (enExample)
AU (2) AU2013272330B2 (enExample)
CA (1) CA2875841C (enExample)
DK (2) DK3456334T3 (enExample)
ES (2) ES2847424T3 (enExample)
HR (1) HRP20190162T1 (enExample)
HU (1) HUE042643T2 (enExample)
LT (1) LT2854826T (enExample)
PL (2) PL2854826T3 (enExample)
SI (1) SI2854826T1 (enExample)
TR (1) TR201901771T4 (enExample)
WO (1) WO2013184064A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101915904B1 (ko) 2016-08-12 2018-11-06 한국식품연구원 락토바실러스 인테스티날리스를 포함하는 갱년기 예방 또는 치료용 조성물
KR102120479B1 (ko) * 2018-10-30 2020-06-09 주식회사 종근당바이오 프로바이오틱스를 유효 성분으로 포함하는 이차성 골다공증의 예방 또는 치료용 조성물
US12427174B2 (en) * 2019-02-05 2025-09-30 Biomedit, Inc. Probiotic compositions comprising lactobacillus reuteri strains and methods of use
KR102080498B1 (ko) * 2019-08-23 2020-02-24 정영옥 페룰산 및 유산균을 유효성분으로 포함하는 골감소증 개선 또는 예방용 식품 조성물
JP7596301B2 (ja) * 2019-12-02 2024-12-09 雪印メグミルク株式会社 骨強化剤
CN111718903A (zh) * 2020-06-24 2020-09-29 江南大学 一种筛选可预防和/或治疗骨质疏松的药物的方法
CN114711429B (zh) * 2021-06-08 2023-11-17 青岛蔚蓝生物股份有限公司 一株具有增强骨健康作用的罗伊氏乳杆菌及其应用
CN114634901B (zh) * 2022-05-18 2022-08-30 微康益生菌(苏州)股份有限公司 一种促进骨骼健康的干酪乳杆菌lc16及其培养方法与应用
KR102937770B1 (ko) * 2023-08-09 2026-03-12 국립한국교통대학교산학협력단 골다공증 억제 균주 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105893A2 (en) * 2002-06-13 2003-12-24 Alimentary Health Limited Probiotic therapies
WO2006110088A1 (en) * 2005-04-15 2006-10-19 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation in mammals
EP1918373A1 (en) * 2005-07-26 2008-05-07 School Corporation, Azabu Veterinary Medicine Education Anti-obesity agent and anti-obesity food
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028300A1 (en) * 2006-09-07 2008-03-13 Mcgill University Oral polymeric membrane feruloyl esterase producing bacteria formulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105893A2 (en) * 2002-06-13 2003-12-24 Alimentary Health Limited Probiotic therapies
WO2006110088A1 (en) * 2005-04-15 2006-10-19 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation in mammals
EP1918373A1 (en) * 2005-07-26 2008-05-07 School Corporation, Azabu Veterinary Medicine Education Anti-obesity agent and anti-obesity food
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRENDAN E BOYCE ET AL, "TNF.ALPHA. and pathologic bone resorption", KEIO JOURNAL OF MEDICINE., JP, (20050101), vol. 54, no. 3, doi:10.2302/kjm.54.127, ISSN 0022-9717, pages 127 - 131 *
CHING-YI LAI ET AL, "Preventing Bone Loss and Weight Gain with Combinations of Vitamin D and Phytochemicals", JOURNAL OF MEDICINAL FOOD, (20111101), vol. 14, no. 11, doi:10.1089/jmf.2010.0232, ISSN 1096-620X, pages 1352 - 1362 *
SCHOLZ-AHRENS K E ET AL, "Prebiotics, probiotics, and synbiotics affect mineral absorption, bone mineral content, and bone structure", THE JOURNAL OF NUTRITION, (20070301), vol. 137, no. 3, Suppl. S, pages 838S - 846S *
WALTER J. ET AL., "Host-microbial symbiosis in the vertebrate gastrointestinal tract and the Lactobacillus reuteri paradigm", PNAS, (2011), vol. 108, pages 4645 - 4652 *

Also Published As

Publication number Publication date
KR20150028968A (ko) 2015-03-17
EP2854826A1 (en) 2015-04-08
HRP20190162T1 (hr) 2019-04-05
HUE042643T2 (hu) 2019-07-29
KR20200044134A (ko) 2020-04-28
US20180200313A1 (en) 2018-07-19
US9968643B2 (en) 2018-05-15
EP2854826B9 (en) 2019-05-08
CN104755091A (zh) 2015-07-01
ES2711427T3 (es) 2019-05-03
EP2854826B1 (en) 2018-11-14
PL2854826T3 (pl) 2019-06-28
EP2854826A4 (en) 2016-07-06
AU2013272330A1 (en) 2015-01-15
DK2854826T3 (en) 2019-03-11
AU2018200524B2 (en) 2019-07-18
SI2854826T1 (sl) 2019-03-29
US20150150917A1 (en) 2015-06-04
CA2875841C (en) 2021-02-02
JP2015526389A (ja) 2015-09-10
PL3456334T3 (pl) 2021-05-04
HK1211847A1 (en) 2016-06-03
JP6193981B2 (ja) 2017-09-06
EP3456334A1 (en) 2019-03-20
CA2875841A1 (en) 2013-12-12
AU2018200524A1 (en) 2018-02-15
US10232001B2 (en) 2019-03-19
CN104755091B (zh) 2020-07-21
US10537598B2 (en) 2020-01-21
LT2854826T (lt) 2019-02-11
ES2711427T8 (es) 2019-06-20
DK3456334T3 (da) 2021-01-25
TR201901771T4 (tr) 2019-03-21
WO2013184064A1 (en) 2013-12-12
KR102191537B1 (ko) 2020-12-16
ES2847424T3 (es) 2021-08-03
US20170128501A1 (en) 2017-05-11
US20190142879A1 (en) 2019-05-16
EP3456334B1 (en) 2020-11-11

Similar Documents

Publication Publication Date Title
AU2018200524B2 (en) Selection and use of lactic acid bacteria preventing bone loss in mammals
Zhao et al. Saturated long-chain fatty acid-producing bacteria contribute to enhanced colonic motility in rats
Algieri et al. Intestinal anti-inflammatory effects of probiotics in DNBS-colitis via modulation of gut microbiota and microRNAs
CN113382740A (zh) 包含细菌菌株的组合物
AU2016344770A1 (en) Faecalibacterium prausnitzii and Desulfovibrio piger for use in the treatment or prevention of diabetes and bowel diseases
CN108567800A (zh) 副干酪乳杆菌菌株gmnl-653用于制备抗骨质流失的组合物的用途
Liu et al. The effects of Bacillus subtilis QST713 and β-mannanase on growth performance, intestinal barrier function, and the gut microbiota in weaned piglets
US20240335487A1 (en) Multi-strain probiotic formulation for ameliorating or preventing symptoms of treatment resistant depression
JP6716330B2 (ja) ウロプラキン発現促進剤
Kim et al. 439 methanobrevibacter smithii is found in human duodenum and is associated with altered luminal cytokines
TWI740101B (zh) 降膽固醇之益生菌株的用途
Lawenius et al. Gut microbiota transplantation from young adult mice fails to restore low bone and muscle mass in old mice
HK1211847B (en) Selection and use of lactic acid bacteria preventing bone loss in mammals
Shuangli et al. The mechanism of Bifidobacterium LPL-RH on increasing bone mineral density in ovariectomized osteoporosis rats.
WO2025233488A1 (en) Lactobacillus salivarius strain and uses thereof
Poeker Towards understanding the modulation potential of dietary fibers on intestinal microbiota using human and a novel murine intestinal fermentation model
Carroll et al. 437 Fecal Serine Protease Activity in Patients With IBS is Associated With Specific Alterations in the Intestinal Microbiota
Wang et al. An emerging role of Prevotella histicola on estrogen-deficiency induced bone loss through the gut microbiota-bone axis
WO2026044228A1 (en) Chorismate pathway metabolite compositions and methods of use thereof
Wang et al. 922 Angiotensin Converting Enzyme Modulates Epithelial Cell Apoptosis in a Massive Intestinal Resection Rat Model: Role of At1r Receptor
Class et al. Patent application title: Use of Bifidobacterium Animalis for Treating or Preventing Body Weight Gain and Insulin Resistance Inventors: Jian Shen (Shanghai, CN) Jingjing Wang (Shanghai, CN) Liping Zhao (Shanghai, CN) Martin Saul Obin (West Newton, MA, US) Muriel Derrien (Bures Sur Yvette, FR) Emilie Rocher (Massy, FR) Johan Van Hylckama Vlieg (Marly Le Roi, FR) Assignees: TUFTS UNIVERSITY COMPAGNIE GERVAIS DANONE
Barnes et al. 923 The Addition of Synbiotics to Partial Enteral Nutrition Enhances Intestinal Adaptation in a Piglet Model of Intestinal Failure
Ramadass 924 Glutamine Attenuates the Toxic Effects of Legumes via Stimulation of HSP Production

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired